ArticleWorld journal of clinical oncology2020

Tumor-specific lytic path "hyperploid progression mediated death": Resolving side effects through targeting retinoblastoma or p53 mutant.

Frank-Un Hong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.